STOCK TITAN

Organigram to Report First Quarter Fiscal 2023 Results on January 12, 2023

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary

Organigram Holdings Inc. (NASDAQ: OGI) will report its earnings results for Q1 fiscal 2023, ending November 30, 2022, on January 12, 2023, before market open. A conference call will be held at 8:00 AM Eastern Time on the same day to discuss the results. Participants can register for the call online and will receive access details via email. Organigram is a leading cannabis producer in Canada, focused on high-quality products and expanding its global footprint through various brands and international partnerships.

Positive
  • Organigram is a leading cannabis producer in Canada focused on quality.
  • The company has developed a diverse portfolio of cannabis brands.
Negative
  • None.

TORONTO--(BUSINESS WIRE)-- Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), the parent company of Organigram Inc. (together, the “Company” or “Organigram”), a leading licensed producer of cannabis, announced today it will report earnings results for its first quarter fiscal 2023 ended November 30, 2022, on Thursday, January 12, 2023, before market open.

The Company will host a conference call to discuss its results with details as follows:

Date: Thursday, January 12, 2023
Time: 8:00 am Eastern Time

To register for the conference call, please use this link:
https://conferencingportals.com/event/RUyBPhzX

To ensure you are connected for the full call, we suggest registering a day in advance or at minimum 10 minutes before the start of the call. After registering, a confirmation will be sent through email, including dial in details and unique conference call codes for entry. Registration is open through the live call.

To access the webcast:
https://events.q4inc.com/attendee/655133665
Participants will receive their details via email.

A replay of the webcast will be available within 24 hours after the conclusion of the call at https://www.organigram.ca/investors and will be archived for a period of 90 days following the call.

About Organigram Holdings Inc.

Organigram Holdings Inc. is a NASDAQ Global Select Market and TSX listed company whose wholly-owned subsidiaries include: Organigram Inc. and Laurentian Organic Inc., licensed producers of cannabis and cannabis-derived products in Canada, and The Edibles and Infusions Corporation, a licensed manufacturer of cannabis-infused soft chews in Canada.

Organigram is focused on producing high-quality, cannabis for patients and adult recreational consumers, as well as developing international business partnerships to extend the Company’s global footprint. Organigram has also developed and acquired a portfolio of legal adult-use recreational cannabis brands, including Edison, Big Bag O’ Buds, SHRED, SHRED’ems, Monjour, Laurentian, Tremblant Cannabis and Trailblazer. Organigram operates facilities in Moncton, New Brunswick and Lac-Supérieur, Quebec, with a dedicated edibles manufacturing facility in Winnipeg, Manitoba. The Company is regulated by the Cannabis Act and the Cannabis Regulations (Canada).

This news release contains forward-looking information. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects”, “estimates”, “intends”, “anticipates”, “believes” or variations of such words and phrases or state that certain actions, events, or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results, events, performance or achievements of Organigram to differ materially from current expectations or future results, performance or achievements expressed or implied by the forward-looking information contained in this news release. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information include factors and risks as disclosed in the Company’s most recent annual information form, management’s discussion and analysis and other Company documents filed from time to time on SEDAR (see www.sedar.com) and filed or furnished to the Securities and Exchange Commission on EDGAR (see www.sec.gov). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information included in this news release are made as of the date of this news release and the Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.

For media inquiries:

Paolo De Luca

Chief Strategy Officer

paolo.deluca@organigram.ca

For investor inquiries:

investors@organigram.ca

Source: Organigram Holdings Inc.

FAQ

When will Organigram report its Q1 fiscal 2023 earnings?

Organigram will report its Q1 fiscal 2023 earnings on January 12, 2023.

What time is the conference call for Organigram's earnings results?

The conference call for Organigram's earnings results will be held at 8:00 AM Eastern Time on January 12, 2023.

How can I register for Organigram's earnings conference call?

You can register for Organigram's earnings conference call through the provided link in the press release.

What is the ending date for Organigram's Q1 fiscal 2023?

The ending date for Organigram's Q1 fiscal 2023 is November 30, 2022.

Organigram Holdings Inc. Common Shares

NASDAQ:OGI

OGI Rankings

OGI Latest News

OGI Stock Data

166.12M
75.87M
31.32%
9.73%
2.11%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States of America
Toronto